Skip to content

Clinical Performance Evaluation of a Diagnostic Ultrasound System

Clinical Performance Evaluation of the Vivid Pioneer Diagnostic Ultrasound System

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07066449
Enrollment
60
Registered
2025-07-15
Start date
2025-08-12
Completion date
2026-04-30
Last updated
2025-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Echocardiography

Brief summary

Subjects who are required to undergo transesophageal echocardiography according to the current clinical practice standards will be eligible for enrollment. Subjects will be screened for enrollment in this study against the inclusion and exclusion criteria. After successful screening and enrollment of subjects, the investigators will first use the investigational device to conduct transthoracic echocardiography (TTE), followed by transesophageal echocardiography (TEE). TEE will be conducted after the subject has been anesthetized. To avoid any delay in diagnosis and treatment, after the scan with the investigational device is completed, the probe will be reserved and the console will be switched to the existing commercial cardiac diagnostic ultrasound device in the study site for intraoperative guidance. In the study, each investigator will evaluate the overall image quality, user interface, workflow, user preferences, product preset, and functions of the system, as well as the device's safety and stability and fill out a user feedback questionnaire provided by the Sponsor.

Interventions

None listed

Sponsors

GE Healthcare
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Adults ≥ 18 years old, have autonomous capacity; 2. Subjects who are required to undergo intraoperative transesophageal echocardiography according to the current clinical practice standards; 3. Agree to participate in this study and have signed the subject Informed Consent Form.

Exclusion criteria

1. Subjects who have been previously enrolled in this study or are participating in other clinical trials; 2. Subjects with any medical emergency condition requiring urgent treatment; 3. Pregnant females; 4. Subjects with absolute contraindications of TEE (congenital or acquired upper digestive tract diseases, such as active upper gastrointestinal hemorrhage, esophageal obstruction or stenosis, esophageal tumor, esophageal lacerations and perforations, esophageal diverticula) or relative contraindications (changes in consciousness or lack of cooperation, history of cervical and mediastinal radiotherapy, history of recent esophageal surgery, esophageal varicosity, clotting disorders, cervical disease and injury, active esophagitis, active gastrointestinal ulcers, hiatal hernia, poor cardiopulmonary function, airway damage, pharyngeal space-occupying lesions, etc.), who are expected to be at high risks; 5. Any other subjects who should not participate in this study in the investigator's opinion.

Design outcomes

Primary

MeasureTime frame
The main evaluation indicators include Overall system operation, Reliability, System operability, Overall image quality, etc., and the evaluation results are represented by five grades: Excellent, Very good, Good, Bad, and Very bad.From enrollment to Day 1 (Visit 1)

Other

MeasureTime frame
The other evaluation indicators include Imaging Mode , Structural Heart Disease Workflow Productivity Tools, FlexiSlice Improvements , The results are expressed as a score (5 to 1 point), with higher scores indicating better performanceFrom enrollment to Day1(Visit1)

Countries

China

Contacts

Primary ContactJuan Zhang
yinyinye9157793@126.com+86 18951670387
Backup ContactZhihui Z Zhang, Zhi
zhihui.zhang2@gehealthcare.com+86 18531524215

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026